Mitochondrial and cellular toxicity induced by Fialuridine in human muscle in vitro

Laboratory Investigation

Volumn 76, Issue 4, 1997, Pages 487-495

  Semino Mora, Cristina ^a   Leon Monzon, Marta ^a   Dalakas, Marines C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIALURIDINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DNA REPLICATION; ELECTRON MICROSCOPY; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FAILURE; MITOCHONDRIAL MYOPATHY; MYOGLOBINURIA; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

EID: 0030900269     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ahmed SR (1993). Fialuridine trials suspended (letter). Lancet 342:166.
2. Arnaudo E, Dalakas MC, Shanske S, Moraes CT, DiMauro S, and Schoen EA (1991). Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337:508-510.
3. Askanas V and Engel WK (1975). A new program for investigating adult human skeletal muscle grown aneurally in tissue culture. Neurology 25:58-67.
4. Cheng C-H, Vazquez-Padua M, and Cheng Y-C (1991). Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implications for delayed toxicity. Mol Pharmacol 39:625-628.
5. Cheng C-H and Cheng Y-C (1992). The rale of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the antihuman immunodeficiency virus compound 2′3′-dideoxycytidine. J Biol Chem 267:2856-2859.
6. Colacino JM, Horn JW, Horn DM, and Richardson FC (1996). Incorporation of Fialuridine (FIAU) into mitochondrial-DNA and effects of FIAU on the morphology of mitochondria in human hepatoblastoma cells. Toxicol in vitro 10:297-303.
7. Colacino JM, Malcolm SK, and Jaskunas SR (1994). Effect of Fialuridine on replication of mitochondrial DNA in CEM cells and in human hepatoblastoma cells in culture. Antimicrob Agents Chemother 38:1997-2002.
8. Cui L, Yoon S, Schinazi RF, and Sommadossi JP (1995). Cellular and molecular events leading to mitochondrial toxicity of 1-(2-Deoxy-2-Fluoro-1-β -D-arabinofuranosyl)-5-lodouracil in human liver cells. J Clin Invest 95:555-563.
9. Dalakas MC (1994). HIV or zidovudine myopathy? Neurology 43:971-976.
10. Dalakas MC, Ilia I, Pezeshkpour GH, Laukaitis J, Cohen B, and Griffin JL (1990). Mitochondrial myopathy caused by long-term zidovudine (AZT) therapy. N Engl J Med 322:1098-1105.
11. Dalakas MC, Leon-Monzon M, Bernardini I, Gahl WA, and Jay CA (1994). Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 36:482-487.
12. Dusheiko GM (1994). Fialuridine toxicity: New hopes and false downs. Int Antiviral News 2:22-23.
13. Ericksson S, Xu B, and Clayton DA (1995). Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase. J Biol Chem 270:18929-18934.
14. Guerin JL (1991). Antiviral agents for hepatitis B. Hepatology 14:198-199.
15. Harrington JA, Reardon JE, and Spector T (1993). 3′-Azido-3′-Deoxythymidine (AZT) monophosphate: An inhibitor of exonucleolytic repair of AZT-terminated DNA. Antimicrob Agents Chemother 37:918-920.
16. Hoofnagle JH, Hanson RG, Minuk GY, Pappas C, Schafer DF, Dusheiko GM, Strauss SE, Popper H, and Jones EA (1984). Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 86:150-157.
17. Illa I, Leon-Monzon M, and Dalakas MC (1992). Regenerating and denervated human muscle fibers and satellite cells express neural cell adhesion molecule recognized by monoclonal antibodies to natural killer cells. Ann Neurol 31:46-52.
18. Klecker RW, Katki AG, and Collins JM (1994). Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2′-fluoro-2′-deoxy-β-D-arabinofuranosyl)-5-lodouracil in U-937 and MOLT-4 cells. Mol Pharmacol 46:1204-1209.
19. Konig H, Behr E, Lower J, and Kurth R (1989). Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma. Antimicrob Agents Chemother 33:2109-2114.
20. Korba B and Gerin JL (1992). Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res 19:55-70.
21. Lamperth L, Dalakas MC, Dagani F, Anderson J, and Ferrari R (1991). Abnormal skeletal and cardiac muscle mitochondrial induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest 65:742-751.
22. Lewis W and Dalakas MC (1995). Mitochondrial toxicity of antiviral drugs. Nat Med 1:417-422.
23. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi JP, Watanabe KA, and Perrino FW (1996). Fialuridine and its metabolites inhibit DNA polymerase-y at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A 93:3592-3597.
24. Lewis W, Meyer RR, Simpson JF, Colacino JM, and Perrino FW (1994a). Mammalian DNA polymerases α, β, γ, δ, and ∈ incorporate Fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 33:14620-14624.
25. Lewis W, Simpson JF, and Meyer RR (1994b). Cardiac mitochondrial DNA-polymerase-γ is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 74:344-348.
26. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Yoon Park RN, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE, and Hoofnagle JH (1995). Hepatic failure and lactic acidosis due to Fialuridine (FIAU): An investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333:1099-1105.
27. Perrillo RP (1993). Antiviral therapy of chronic hepatitis B: Past, present and future. J Hepatol 17(Suppl 3):S56-S63.
28. Perrillo RP, Regenstein FG, Bodicky CJ, Campbell CR, Sanders GE, and Sunwoo YC (1985). Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type B. Gastroenterology 88:780-786.
29. Richardson FC, Engelhardt JA, and Bowsher RR (1994). Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration. Proc Natl Acad Sci U S A 91:12003-12007.
30. Sato T and DiMauro S (1991). Progress in neurology, vol 7. New York: Raven Press.
31. Semino-Mora MC, Leon-Monzon ME, and Dalakas MC (1994a). The effect of L-carnitine on the AZT-induced destruction of human myotubes: Part I - L-carnitine prevents the myotoxicity of AZT in vivo. Lab Invest 70:102-112.
32. Semino-Mora MC, Leon-Monzon ME, and Dalakas MC (1994b). The effect of L-carnitine on the AZT-induced destruction of human myotubes: Part II - Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. Lab Invest 71:773-781.
33. Staschke KA and Colacino JM (1994). Priming of duck hepatitis B virus reverse transcription in vitro: Premature termination of primer DNA induced by the 5′-triphosphate of Fialuridine. J Virol 68:8265-8269.
34. Staschke KA, Colacino JM, Mabry TE, and Jones CD (1994). The in vitro anti-hepatitis B virus activity of FIAU [1-(2′-deoxy-2′fluoro-1-β-D-arabinofuranosyl-5-lodo-uracil] is selective, reversible, and determined, at least in part, by the host cell. Antiviral Res 23:45-61.
35. Swartz MN (1995). Mitochondrial toxicity. New adverse drug effects. N Engl J Med 333:1146-1148.
36. Szmuness W (1978). Hepatocellular carcinoma and the hepatitis B virus: Evidence for a casual association. Prog Med Virol 24:40-69.
37. Weibel ER (1969). Stereological principles for morphometry in electron microscopy cytology. Int Rev Cytol 26:235-302.